80jili net
Ange Postecoglou searching for answers over Tottenham’s injury crisishttps://static.bangkokpost.com/media/content/20241123/c1_2907247_241123060456_700.jpg
China stocks have whipsawed in recent months on stimulus hopes and disappointment, along with the threat of new tariffs under President-elect Donald Trump. Still, several stocks are showing strength. ( ) rivals ( ) and ( ) are near buy points, along with travel plays ( ) and ( ) as well as messaging and gaming giant ( ). Investors should pay attention to many other Chinese stocks, including e-commerce titan ( ), ( ), search giant ( ), data center play ( ), online entertainment concern ( ) and gaming giant ( ). Don't forget other EV makers, such as ( ), ( ) and ( ), as well as smartphone giant-turned-EV maker ( ). Top China ETFs Investors wary of buying an individual Chinese stock could choose ETFs such as KraneShares CSI China Internet ETF ( ), iShares China Large-Cap ETF ( ) and Xtrackers Harvest CSI 300 China A-Shares ETF ( ). But these ETFs are prone to big gap-ups and -downs as well. Top China Stocks To Buy Or Watch Now Trip.com Stock Trip.com is a China-based online travel site operator. It's benefited from a travel boom after China's long Covid restrictions were lifted in late 2022. Q3 earnings rose 25% vs. a year earlier, the third straight quarter of decelerating growth, as comparisons get tougher. Revenue gained 20%, picking up from 13% in Q2. Travel seems be on the upswing globally. Trip.com stock gapped out of a consolidation on Dec. 9, part of a big base-on-base formation. Shares soon pulled back into the buy zone and are now finding support at the 21-day line. BYD Stock The world's leading EV maker, BYD produces fully battery electric vehicles (BEVs) and plug-in hybrids (PHEVs). It's also one of the world's largest battery makers. BYD earnings rose 16% in Q3 vs. a year earlier. Revenue grew 29%, accelerating from 26% in Q2 and Q1's 1% decline. Notably, BYD revenue topped Tesla's for the first time. Q4 revenue growth should accelerate. In Q3 BYD sold a record 1,134,892 vehicles, up 37.3% vs. a year earlier and 7.6% vs. Q2's 986,720. PHEV sales soared 75.6% vs. a year before to 685,830. BEV passenger sales came in at 443,426, up 2.7% vs. a year earlier and 4.1% vs. Q2. A rapid expansion of models, technology and markets has fueled BYD, which is building factories in Asia, Europe and Latin America. In Q4, BYD is on track to sell well over 1.5 million EVs, easily clearing a full-year target of 4 million vehicles. BYD should comfortably top Tesla in BEV sales, even as it focuses on PHEVs. BYD will release December, Q4 and 2024 sales figures on Jan. 1-2. In early October, BYD topped the official 36.27 buy point, and quickly hit a two-year high of 42. But shares pulled back well below the buy point, forging a new base with a 42 buy point. Investors could use the Dec. 11 high of 37 as an early entry. The Chinese stock is Hong Kong listed and trades over the counter in the U.S., so its U.S. stock chart shows lots of mini gap-ups and -downs. ZK Stock Zeekr is a Chinese EV maker. It's actually a unit of China auto giant Geely and is moving toward integrating another Geely unit, Lynx. Zeekr makes BEVs and PHEVs. It competes in the modest-to-mainstream markets, competing against BYD, XPeng, Tesla and others. Zeekr is still losing money, though sales growth remains strong at 36% in Q3. The startup will release December, Q4 and 2024 sales figures on Jan. 1. ZK stock came public in the U.S. at 21 a share in May, hitting a record 32.24 on May 13, the second day of trading. Shares then plunged to 13 on Aug. 12 before rebounding. Shares broke out of a 36%-deep consolidation on Dec. 26, but fell back sharply the next day. The consolidation could be viewed as a huge handle to a very deep base. Zeeker, like fellow startups XPeng, Nio and Li Auto, is prone to big daily swings. Tencent Stock Tencent is a massive messaging and gaming giant. Its WeChat super app is the envy of the world. Strong gaming demand has fueled a big surge in earnings. Q3 earnings leapt 42% vs. a year earlier, on a strong pace but snapping a seven-quarter string of accelerating growth. Revenue growth has picked up for the last two quarters, to 12%. Tencent stock is in a 20%-deep consolidation, with a 61.60 buy point. Shares are mostly trading around the 50-day line, currently trading above the 50-day. The base forged just above a flat base and at the top of a mammoth consolidation going back to January 2023. Tencent is Hong Kong listed and trades over the counter in the U.S., so its U.S. stock chart shows lots of mini gap-ups and -downs. Atour Lifestyle Holdings Atour Lifestyle owns and manages a hotel chain in China. As of June 30, there were 1,412 hotels across Atour's hotel network, with 123 new openings in the second quarter, a quarterly record. The company says it's the largest upper-midscale hotel chain in China in terms of rooms. Chinese travel roared back in 2023 as Covid restrictions were lifted. Atour earnings for Q3 rose 47% with revenue up 53%. Shares of China stock Atour nearly doubled from early August to a 52-week high of 29.15 on Oct. 7. Shares have consolidated, briefly breaking higher on Dec. 9 and Dec. 24, but pulling back quickly.Nancy Mace launches merch line for Capitol Hill bathroom fight
The new, 12-team College Football Playoff brings with it a promise to be bigger, more exciting, more lucrative. Perfect or 100% fair? Well, nobody ever believed that. The first expanded playoff bracket unveiled Sunday left a presumably deserving Alabama team on the sideline in favor of an SMU squad that finished with a better record after playing a schedule that was not as difficult. It ranked undefeated Oregon first but set up a possible rematch against Ohio State, the team that came closest to beating the Ducks this year. It treated underdog Boise State like a favorite and banged-up Georgia like a world beater at No. 2. It gave Ohio State home-field advantage against Tennessee for reasons it would take a supercomputer to figure out. It gave the sport the multiweek tournament it has longed for, but also ensured there will be plenty to grouse about between now and when the trophy is handed out on Jan. 20 after what will easily be the longest college football season in history. All of it, thankfully, will be sorted out on the field starting with first-round games on campuses Dec. 20 and 21, then over three succeeding rounds that will wind their way through traditional bowl sites. Maybe Oregon coach Dan Lanning, whose undefeated Ducks are the favorite to win it all, put it best when he offered: "Winning a national championship is not supposed to be easy.” Neither, it turns out, is figuring out who should play for it. The Big Ten will lead the way with four teams in the tournament, followed by the SEC with three and the ACC with two. The lasting memory from the inaugural bracket will involve the decision that handed the ACC that second bid. Alabama of the SEC didn't play Saturday. SMU of the ACC did. The Mustangs fell behind by three touchdowns to Clemson before coming back to tie. But they ultimately lost 34-31 on a 56-yard field goal as time expired. “We were on pins and needles,” SMU coach Rhett Lashley said. “Until we saw the name ‘SMU’ up there, we were hanging on the edge. We're really, really happy and thankful to the committee for rewarding our guys for their total body of work." The Mustangs only had two losses, compared to three for the Crimson Tide. Even though SMU's schedule wasn't nearly as tough, the committee was impressed by the way the Mustangs came back against Clemson. “We just felt, in this particular case, SMU had the nod above Alabama,” said Michigan athletic director Warde Manuel, the chairman of the selection committee. “But it’s no disrespect to Alabama’s strength of schedule. We looked at the entire body of work for both teams.” Alabama athletic director Greg Byrne was gracious, up to a point. “Disappointed with the outcome and felt we were one of the 12 best teams in the country,” he said on social media. He acknowledged — despite all of Alabama’s losses coming against conference opponents this season — that the Tide’s push to schedule more games against teams from other major conferences in order to improve its strength of schedule did not pay off this time. “That is not good for college football," Byrne said. Georgia, the SEC champion, was seeded second; Boise State, the Mountain West champion, earned the third seed; and Big 12 titlist Arizona State got the fourth seed and the fourth and final first-round bye. All will play in quarterfinals at bowl games on Dec. 31-Jan. 1. Clemson stole a bid and the 12th seed with its crazy win over SMU, the result that ultimately cost Alabama a spot in the field. The Tigers moved to No. 16 in the rankings, but got in as the fifth-best conference winner. The conference commissioners' idea to give conference champions preferable treatment in this first iteration of the 12-team playoff could be up for reconsideration after this season. The committee actually ranked Boise State, the Mountain West Champion, at No. 9 and Big 12 champion Arizona State at No. 12, but both get to skip the first round. Another CFP guideline: There’s no reseeding of teams after each round, which means no break for Oregon. The top-seeded Ducks will face the winner of Tennessee-Ohio State in the Rose Bowl. Oregon beat Ohio State 32-31 earlier this year in one of the season’s best games. No. 12 Clemson at No. 5 Texas, Dec. 21. Clemson is riding high after the SMU upset, while Texas is 0-2 against Georgia and 11-0 vs. everyone else this season. The winner faces ... Arizona State in the Peach Bowl. Huh? No. 11 SMU at No. 6 Penn State, Dec. 21. The biggest knock against the Mustangs was that they didn't play any big boys with that 60th-ranked strength of schedule. Well, now they get to. The winner faces ... Boise State in the Fiesta Bowl. Yes, SMU vs. Boise was the quarterfinal we all expected. No. 10 Indiana at No. 7 Notre Dame, Dec. 20. Hoosiers coach Curt Cignetti thought his team deserved a home game. Well, not quite but close. The winner faces ... Georgia in the Sugar Bowl. The Bulldogs got the No. 2 seed despite a throwing-arm injury to QB Carson Beck. But what else was the committee supposed to do? No. 9 Tennessee at No. 8 Ohio State , Dec. 21. The Buckeyes (losses to Oregon, Michigan) got home field over the Volunteers (losses to Arkansas, Georgia) in a matchup of programs with two of the biggest stadiums in football. The winner faces ... Oregon in the Rose Bowl. Feels like that matchup should come in the semifinals or later. Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football
'Fundamental act of justice': President Biden speaks on Assad's fall in Syria
Global Commercial Waterproof Drone Market Set to Experience Exponential Growth: Key Trends and Opportunities | Valuates ReportsSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec 8, 2024-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today data from a five-year follow-up of the pivotal Phase III POLARIX study evaluating Polivy ® (polatuzumab vedotin-piiq) in combination with Rituxan ® (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) in people with untreated diffuse large B-cell lymphoma (DLBCL). Data were presented in an oral session at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, December 7-10, 2024 in San Diego, California. This latest analysis conducted after a median follow-up of 60.9 months, includes descriptive data on primary and secondary endpoints, as well as safety results. “POLARIX was the first trial to elevate treatment standards for frontline diffuse large B-cell lymphoma in 20 years and we are additionally encouraged by the five-year follow-up results,” said Levi Garraway, M.D., Ph.D., Genentech’s chief medical officer and head of Global Product Development. “More than 38,000 people worldwide have been treated with Polivy in combination with R-CHP and these data continue to underscore its potential to improve outcomes for people diagnosed with this aggressive lymphoma.” Follow-up exploratory analysis after five-years indicated a positive trend in overall survival (OS) in the intent-to-treat (ITT) population in favor of Polivy in combination with R-CHP compared to Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). Results showed a trend in reduction in the risk of death (HR 0.85; 95% CI: 0.63–1.15) for people with previously untreated DLBCL with the Polivy combination, an improvement on the three-year follow-up data (HR 0.94; 95% CI: 0.67–1.33). The five-year analysis of POLARIX indicates that the full difference in OS between treatment arms has yet to be observed and an additional two years of follow-up will continue. “Diffuse large B-cell lymphoma is a notoriously challenging cancer to treat, however, Polivy in combination with R-CHP has shown to be a critical advance for patients by helping to reduce relapse and disease progression,” said Gilles Salles, M.D., Ph.D., chief of Lymphoma Service, Division of Hematological Malignancies, Memorial Sloan Kettering Cancer Center, New York. “The survival trend seen in this follow-up analysis reinforces the potential impact of frontline treatment with Polivy in combination with R-CHP and its role as a standard of care therapy.” In addition to the positive trend in OS, an observational analysis suggested nearly 25% fewer follow-up treatments such as radiation, systemic chemotherapy and CAR-T cell therapy were needed in patients receiving Polivy in combination with R-CHP compared to those treated with R-CHOP (38.3% versus 61.7%). At five years of follow-up, benefits in progression-free survival and disease-free survival with Polivy in combination with R-CHP were maintained, consistent with the three-year follow-up data, reinforcing the potential of Polivy in combination with R-CHP to provide durable and lasting remissions. The latest follow-up data also showed a numerical reduction in death related to patients’ lymphoma in those treated with Polivy in combination with R-CHP compared to those treated with R-CHOP (9.0% versus 11.4%). The safety profile remains consistent with the known profiles of the individual study medicines with no new safety signals observed, reinforcing the positive benefit-risk profile of this Polivy combination. Results from an expanded cohort of 1,000 patients including global and Chinese patients demonstrated comparability to the global ITT population. Polivy in combination with R-CHP is currently approved for the treatment of first-line (1L) DLBCL in more than 90 countries worldwide including the U.S., countries throughout the EU, the U.K., Japan, Canada and China. Genentech continues to work with health authorities around the world to bring this treatment regimen to even more patients. Genentech aims to offer various treatment options for DLBCL that meet the diverse needs of patients and healthcare systems. In an effort to elevate treatment standards even further, Genentech is exploring Polivy in combination with other molecules, including its bispecific antibodies. Studies include the Phase III SUNMO trial evaluating the efficacy and safety of subcutaneously administered Lunsumio ® (mosunetuzumab-axgb) in combination with intravenous (IV) Polivy versus IV Rituxan plus gemcitabine and oxaliplatin (R-GemOx) in second-line or later DLBCL, and the Phase III SKYGLO trial investigating the efficacy of Polivy in combination with R-CHP and Columvi ® (glofitamab-gxbm) versus Polivy in combination with R-CHP in 1L DLBCL. About the POLARIX Study POLARIX [ NCT03274492 ] is an international Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety and pharmacokinetics of Polivy ® (polatuzumab vedotin-piiq) plus Rituxan ® (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) versus Rituxan, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Eight-hundred and seventy-nine patients were randomized 1:1 to receive either Polivy plus R-CHP plus a vincristine placebo for six cycles, followed by Rituxan for two cycles; or R-CHOP plus a Polivy placebo for six cycles, followed by two cycles of Rituxan. The primary outcome measure is progression-free survival as assessed by the investigator using the Lugano Response Criteria for malignant lymphoma. POLARIX is being conducted in collaboration with The Lymphoma Study Association (LYSA) and The Lymphoma Academic Research Organisation (LYSARC). About Diffuse Large B-Cell Lymphoma Diffuse large B-cell lymphoma (DLBCL) is an aggressive (fast-growing) blood cancer and is the most common form of non-Hodgkin’s lymphoma (NHL) in the U.S. While many people with DLBCL are responsive to treatment, the majority of those who relapse or are refractory to subsequent treatments have poor outcomes. DLBCL not otherwise specified is the most common category of large B-cell lymphoma (LBCL) and accounts for about 80% or more of cases. It applies to cases that do not fall into any specific disease subgroups of LBCL. About Polivy ® (polatuzumab vedotin-piiq) Polivy is a first-in-class anti-CD79b antibody-drug conjugate (ADC). The CD79b protein is expressed specifically in the majority of B cells, an immune cell impacted in some types of non-Hodgkin’s lymphoma (NHL), making it a promising target for the development of new therapies. Polivy binds to cancer cells such as CD79b and destroys these B cells through the delivery of an anti-cancer agent, which is thought to minimize the effects on normal cells. Polivy is being developed by Genentech using Pfizer ADC technology and is currently being investigated for the treatment of several types of NHL. Polivy U.S. Indication Polivy is a prescription medicine used with other medicines (a rituximab product, cyclophosphamide, doxorubicin, and prednisone) as a first treatment for adults who have moderate to high risk diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL). Polivy is a prescription medicine used with other medicines, bendamustine and a rituximab product, to treat DLBCL in adults who have progressed after at least 2 prior therapies. Important Safety Information Possible serious side effects Everyone reacts differently to Polivy therapy, so it’s important to know what the side effects are. Some people who have been treated with Polivy have experienced serious to fatal side effects. Your doctor may stop or adjust your treatment if any serious side effects occur. Be sure to contact your healthcare team if there are any signs of these side effects. Nerve problems in your arms and legs: This may happen as early as after your first dose and may worsen with every dose. Your doctor will monitor for signs and symptoms, such as changes in your sense of touch, numbness or tingling in your hands or feet, nerve pain, burning sensation, any muscle weakness, or changes to your walking pattern Infusion-related reactions: You may experience fever, chills, rash, breathing problems, low blood pressure, or hives within 24 hours of your infusion Low blood cell counts: Treatment with Polivy can cause severe low blood cell counts. Your doctor will monitor your blood counts throughout treatment with Polivy Infections: If you have a fever of 100.4°F (38°C) or higher, chills, cough, or pain during urination, contact your healthcare team. Your doctor may also give you medication before giving you Polivy, which may prevent some infections Rare and serious brain infections: Your doctor will monitor closely for signs and symptoms of these types of infections. Contact your doctor if you experience confusion, dizziness or loss of balance, trouble talking or walking, or vision changes Tumor lysis syndrome: Caused by the fast breakdown of cancer cells. Signs include nausea, vomiting, diarrhea, and lack of energy Potential harm to liver: Some signs include tiredness, weight loss, pain in the abdomen, dark urine, and yellowing of your skin or the white part of your eyes. You may be at higher risk if you already had liver problems or you are taking other medication Side effects seen most often The most common side effects during treatment were Nerve problems in arms and legs Nausea Tiredness or lack of energy Diarrhea Constipation Hair loss Redness and sores of the lining of the mouth, lips, throat, and digestive tract Polivy may lower your red or white blood cell counts and increase uric acid levels. Polivy may not be for everyone. Talk to your doctor if you are Pregnant or think you are pregnant: Data have shown that Polivy may harm your unborn baby Planning to become pregnant: Women should avoid getting pregnant while taking Polivy. Women should use effective contraception during treatment and for 3 months after their last Polivy treatment. Men taking Polivy should use effective contraception during treatment and for 5 months after their last Polivy treatment Breastfeeding: Women should not breastfeed while taking Polivy and for 2 months after the last dose These may not be all the side effects. Talk to your healthcare provider for more information about the benefits and risks of Polivy treatment. You may report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch . You may also report side effects to Genentech at (888) 835-2555. Please see the full Prescribing Information and visit https://www.Polivy.com for additional Important Safety Information. About Lunsumio ® (mosunetuzumab-axgb) Lunsumio is a first-in-class CD20xCD3 T-cell engaging bispecific antibody designed to target CD20 on the surface of B cells and CD3 on the surface of T cells. This dual targeting activates and redirects a patient’s existing T cells to engage and eliminate target B cells by releasing cytotoxic proteins into the B cells. A robust clinical development program for Lunsumio is ongoing, investigating the molecule as a monotherapy and in combination with other medicines, for the treatment of people with B-cell non-Hodgkin’s lymphomas, including follicular lymphoma and diffuse large B-cell lymphoma, and other blood cancers. Lunsumio U.S. Indication Lunsumio (mosunetuzumab-axgb) is a prescription medicine used to treat adults with follicular lymphoma whose cancer has come back or did not respond to previous treatment, and who have already received two or more treatments for their cancer. It is not known if Lunsumio is safe and effective in children. The conditional approval of Lunsumio is based on response rate. There are ongoing studies to establish how well the drug works. What is the most important information I should know about Lunsumio? Lunsumio may cause Cytokine Release Syndrome (CRS), a serious side effect that is common during treatment with Lunsumio and can also be severe or life-threatening. Get medical help right away if you develop any signs or symptoms of CRS at any time, including: fever of 100.4°F (38°C) or higher chills low blood pressure fast or irregular heartbeat tiredness or weakness difficulty breathing headache confusion feeling anxious dizziness or light-headedness nausea vomiting Due to the risk of CRS, you will receive Lunsumio on a “step-up dosing schedule.” The step-up dosing schedule is when you receive smaller “step-up” doses of Lunsumio on Day 1 and Day 8 of your first cycle of treatment You will receive a higher dose of Lunsumio on Day 15 of your first cycle of treatment If your dose of Lunsumio is delayed for any reason, you may need to repeat the step-up dosing schedule Before each dose in Cycle 1 and Cycle 2, you will receive medicines to help reduce your risk of CRS Your healthcare provider will check you for CRS during treatment with Lunsumio and may treat you in a hospital if you develop signs and symptoms of CRS. Your healthcare provider may temporarily stop or completely stop your treatment with Lunsumio, if you have severe side effects. What are the possible side effects of Lunsumio? Lunsumio may cause serious side effects, including: neurologic problems. Lunsumio can cause serious and life-threatening neurological problems. Your healthcare provider will check you for neurologic problems during treatment with Lunsumio. Your healthcare provider may also refer you to a healthcare provider who specializes in neurologic problems. Tell your healthcare provider right away if you develop any signs or symptoms of neurologic problems during or after treatment with Lunsumio, including: headache numbness and tingling of the arms, legs, hands, or feet dizziness confusion and disorientation difficulty paying attention or understanding things forgetting things or forgetting who or where you are trouble speaking, reading, or writing sleepiness or trouble sleeping tremors loss of consciousness seizures muscle problems or muscle weakness loss of balance or trouble walking tiredness serious infections. Lunsumio can cause serious infections that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment. Tell your healthcare provider right away if you develop any signs or symptoms of infection during treatment with Lunsumio, including: fever of 100.4° F (38° C) or higher chest pain tiredness shortness of breath painful rash sore throat pain during urination feeling weak or generally unwell hemophagocytic lymphohistiocytosis (HLH) . Lunsumio can cause overactivity of the immune system, a condition called hemophagocytic lymphohistiocytosis. HLH can be life-threatening and has led to death in people treated with Lunsumio. Your health care provider will check you for HLH especially if your CRS lasts longer than expected. Signs and symptoms of HLH include: fever enlarged spleen easy bruising low blood cell counts liver problems low blood cell counts. Low blood cell counts are common during treatment with Lunsumio and can also be serious or severe. Your healthcare provider will check your blood cell counts during treatment with Lunsumio. Lunsumio can cause the following low blood cell counts: low white blood cell counts (neutropenia). Low white blood cells can increase your risk for infection low red blood cell counts (anemia). Low red blood cells can cause tiredness and shortness of breath low platelet counts (thrombocytopenia). Low platelet counts can cause bruising or bleeding problems growth in your tumor or worsening of tumor related problems (tumor flare). Lunsumio can cause serious or severe worsening of your tumor. Tell your healthcare provider if you develop any of these signs or symptoms of tumor flare during your treatment with Lunsumio: chest pain cough trouble breathing tender or swollen lymph nodes pain or swelling at the site of the tumor Your healthcare provider may temporarily stop or permanently stop treatment with Lunsumio if you develop severe side effects. The most common side effects of Lunsumio include: tiredness, rash, fever, and headache. The most common severe abnormal blood test results with Lunsumio include: decreased phosphate, increased glucose, and increased uric acid levels. Before receiving Lunsumio, tell your healthcare provider about all of your medical conditions, including if you: have ever had an infusion reaction after receiving Lunsumio have an infection, or have had an infection in the past which lasted a long time or keeps coming back have or have had Epstein-Barr Virus are pregnant or plan to become pregnant. Lunsumio may harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Lunsumio Females who are able to become pregnant: your healthcare provider should do a pregnancy test before you start treatment with Lunsumio you should use an effective method of birth control (contraception) during your treatment and for 3 months after the last dose of Lunsumio are breastfeeding or plan to breastfeed. It is not known if Lunsumio passes into your breast milk. Do not breastfeed during treatment and for 3 months after the last dose of Lunsumio Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. What should I avoid while receiving Lunsumio? Do not drive, operate heavy machinery, or do other dangerous activities if you develop dizziness, confusion, tremors, sleepiness, or any other symptoms that impair consciousness until your signs and symptoms go away. These may be signs and symptoms of CRS or neurologic problems. These are not all the possible side effects of Lunsumio. Talk to your healthcare provider for more information about the benefits and risks of Lunsumio. You may report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch . You may also report side effects to Genentech at (888) 835-2555. Please see Important Safety Information, including Serious Side Effects, as well as the Lunsumio full Prescribing Information and Medication Guide or visit https://www.Lunsumio.com . About Columvi ® (glofitamab-gxbm) Columvi is a CD20xCD3 T-cell engaging bispecific antibody designed to target CD3 on the surface of T cells and CD20 on the surface of B cells. Columvi was designed with a novel 2:1 structural format. This T-cell engaging bispecific antibody is engineered to have one region that binds to CD3, a protein on T cells, a type of immune cell, and two regions that bind to CD20, a protein on B cells, which can be healthy or malignant. This dual-targeting brings the T cell in close proximity to the B cell, activating the release of cancer cell-killing proteins from the T cell. Columvi is part of Genentech’s broad and industry-leading CD20xCD3 T-cell-engaging bispecific antibody clinical development program that also includes Lunsumio ® (mosunetuzumab), which aims to provide tailored treatment options that suit the diverse needs, preferences, and experiences of people with blood cancers and healthcare systems. Genentech is investigating Columvi as a monotherapy and in combination with other medicines for the treatment of diffuse large B-cell lymphoma and mantle cell lymphoma. Columvi U.S. Indication Columvi (glofitamab-gxbm) is a prescription medicine to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) or large B-cell lymphoma (LBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory), and who have received 2 or more prior treatments for their cancer. It is not known if Columvi is safe and effective in children. The conditional approval of Columvi is based on response rate and durability of response. There are ongoing studies to establish how well the drug works. What is the most important information I should know about Columvi? Columvi can cause Cytokine Release Syndrome (CRS), a serious side effect that is common during treatment with Columvi, and can also be serious and lead to death. Call your healthcare provider or get emergency medical help right away if you develop any signs or symptoms of CRS, including: fever of 100.4°F (38°C) or higher chills or shaking fast or irregular heartbeat dizziness or light-headedness trouble breathing shortness of breath Due to the risk of CRS, you will receive Columvi on a “step-up dosing schedule”. A single dose of a medicine called obinutuzumab will be given to you on the first day of your first treatment cycle (Day 1 of Cycle 1). You will start the Columvi step-up dosing schedule a week after the obinutuzumab dose. The step-up dosing schedule is when you receive smaller “step-up” doses of Columvi on Day 8 and Day 15 of Cycle 1. This is to help reduce your risk of CRS. You should be hospitalized during your infusion and for 24 hours after receiving the first step-up dose on Day 8. You should be hospitalized during your infusion and for 24 hours after receiving the second step-up dose on Day 15 if you experienced CRS during the first step-up dose. You will receive your first full dose of Columvi a week after the second step-up dose (this will be Day 1 of Cycle 2). If your dose of Columvi is delayed for any reason, you may need to repeat the “step-up dosing schedule”. If you had more than mild CRS with your previous dose of Columvi, you should be hospitalized during and for 24 hours after receiving your next dose of Columvi. Before each dose of Columvi, you will receive medicines to help reduce your risk of CRS and infusion-related reactions. Your healthcare provider will monitor you for CRS during treatment with Columvi and may treat you in a hospital if you develop signs and symptoms of CRS. Your healthcare provider may temporarily stop or completely stop your treatment with Columvi if you have severe side effects. Carry the Columvi Patient Wallet Card with you at all times and show it to all of your healthcare providers. The Columvi Patient Wallet Card lists the signs and symptoms of CRS you should get emergency medical help for right away. What are the possible side effects of Columvi? Columvi may cause serious side effects, including: Cytokine Release Syndrome. Neurologic problems. Columvi can cause serious neurologic problems that may lead to death. Your healthcare provider will monitor you for neurologic problems during treatment with Columvi. Your healthcare provider may also refer you to a healthcare provider who specializes in neurologic problems. Tell your healthcare provider right away if you develop any signs or symptoms of neurologic problems, including: headache confusion and disorientation difficulty paying attention or understanding things trouble speaking sleepiness memory problems numbness, tingling, or weakness of the hands or feet dizziness shaking (tremors) Serious Infections. Columvi can cause serious infections that may lead to death. Your healthcare provider will monitor you for signs and symptoms of infection and treat you as needed. Tell your healthcare provider right away if you develop any signs of an infection, including: fever, chills, weakness, cough, shortness of breath, or sore throat. Growth in your tumor or worsening of tumor related problems (tumor flare). Tell your healthcare provider if you get any of these signs or symptoms of tumor flare: tender or swollen lymph nodes pain or swelling at the site of the tumor chest pain cough trouble breathing The most common side effects of Columvi include: CRS, muscle and bone pain, rash, and tiredness. The most common severe abnormal lab test results with Columvi include: decreased white blood cells, decreased phosphate (an electrolyte), increased uric acid levels, and decreased fibrinogen (a protein that helps with blood clotting). Your healthcare provider may temporarily stop or completely stop treatment with Columvi if you develop certain side effects. Before receiving Columvi, tell your healthcare provider about all of your medical conditions, including if you: have an infection have kidney problems are pregnant or plan to become pregnant. Columvi may harm your unborn baby Females who are able to become pregnant: Your healthcare provider should do a pregnancy test before you start treatment with Columvi. You should use effective birth control (contraception) during treatment and for 1 month after your last dose of Columvi. Talk to your healthcare provider about what birth control method is right for you during this time. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Columvi. are breastfeeding or plan to breastfeed. Columvi may pass into your breast milk. Do not breastfeed during treatment and for 1 month after your last dose of Columvi. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. What should I avoid while receiving Columvi? Do not drive, operate heavy machinery, or do other dangerous activities if you develop dizziness, confusion, shaking (tremors), sleepiness, or any other symptoms that impair consciousness until your signs and symptoms go away. These may be signs and symptoms of neurologic problems. These are not all the possible side effects of Columvi. Talk to your health care provider for more information about the benefits and risks of Columvi. You may report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch . You may also report side effects to Genentech at (888) 835-2555. Please see Important Safety Information, including Serious Side Effects , as well as the Columvi full Prescribing Information and Medication Guide or visit https://www.Columvi.com About Genentech in Hematology For more than 20 years, Genentech has been developing medicines with the goal to redefine treatment in hematology. Today, we’re investing more than ever in our effort to bring innovative treatment options to people with diseases of the blood. For more information visit http://www.gene.com/hematology . About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com . Dr. Salles has financial interests related to Roche and Genentech. View source version on businesswire.com : https://www.businesswire.com/news/home/20241208818007/en/ CONTACT: Media Contact: Kristen Ingram, (650) 467-6800Advocacy Contact: Catherine Creme Henry, (202) 258-8228Investor Contacts: Loren Kalm, (650) 225-3217 Bruno Eschli, 011 41 61 687 5284 KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH PHARMACEUTICAL CLINICAL TRIALS ONCOLOGY SOURCE: Genentech Copyright Business Wire 2024. PUB: 12/08/2024 12:30 PM/DISC: 12/08/2024 12:30 PM http://www.businesswire.com/news/home/20241208818007/en
I worked in Silicon Valley for a decade. Here are 9 ways I managed stress and boosted productivity.APC Faction, Alia Clash Over Alleged Call For Akume’s Sack
10 Things You Should Know Before Buying A Drone (New Or Used)
Ware scores 17 points as UT Arlington knocks off UL Monroe 77-68Arsenal moves up to second in the Premier League with a 1-0 win over IpswichBOWLING GREEN, Ky. (AP) — Don McHenry scored seven of his 29 points in overtime to lead Western Kentucky over Murray State 81-76 on Saturday. McHenry hit a go-ahead 3-pointer with 39 seconds left and two free throws with 15 remaining to rally the Hilltoppers (7-3). He added five rebounds. Babacar Faye scored 17 and grabbed nine rebounds. Khristian Lander had 12 points. Jacobi Wood led the way for the Racers (6-3) with 22 points, seven rebounds and six assists. Nick Ellington totaled 15 points and seven rebounds. AJ Ferguson pitched in with 13 points, seven rebounds and two steals. Faye put up eight points in the first half for Western Kentucky, which trailed 39-33. McHenry led the Hilltoppers with 15 second-half points and he hit the game-tying layup with 35 seconds left to send the game to overtime tied at 67. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .
Global Commercial Waterproof Drone Market Set to Experience Exponential Growth: Key Trends and Opportunities | Valuates Reports 12-08-2024 06:51 PM CET | Advertising, Media Consulting, Marketing Research Press release from: Valuates Reports Commercial Waterproof Drone Market Commercial waterproof drone is an unmanned aerial vehicle (UAV) specifically designed to operate in and around water environments. Unlike conventional drones, a waterproof drone is built to withstand exposure to water, allowing it to land on water surfaces, float, and even submerge to a certain depth for underwater exploration and data collection. The global Commercial Waterproof Drone market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030. Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-0F13037/Global_Commercial_Waterproof_Drone_Market_Research_Report_2022 Major Trends: 1.Increasing Demand for Drones in Harsh Environments: Commercial waterproof drones are gaining traction in industries like agriculture, construction, mining, and search and rescue operations, where drones need to operate in challenging and wet environments. 2.Advancements in Drone Technology: Continuous innovations in waterproofing technologies, battery life, and payload capacity are enhancing the performance of commercial drones, making them more reliable in diverse weather conditions. 3.Rising Adoption in Industrial Applications: Drones are being increasingly used in sectors such as oil & gas, agriculture, and environmental monitoring, where the ability to withstand wet conditions improves operational efficiency. 4.Integration with AI and Automation: The incorporation of artificial intelligence, machine learning, and automation in commercial waterproof drones is enabling improved navigation, data processing, and real-time decision-making. 5.Government Initiatives and Regulations: Governments across the world are promoting drone technology through regulations and incentives. This has fostered the growth of waterproof drones for commercial use, particularly for surveillance and monitoring purposes in disaster-prone areas. Challenges: 1.High Manufacturing Costs: The technology required to make drones waterproof adds to the production costs, making these drones more expensive than regular drones, which can limit adoption among small to medium-sized businesses. 2.Limited Battery Life: While battery technology has improved, it still poses a challenge for long-duration flights, especially in commercial applications that demand extended operational hours in challenging environments. Purchase Regional Report: https://reports.valuates.com/request/regional/QYRE-Auto-0F13037/Global_Commercial_Waterproof_Drone_Market_Research_Report_2022 By Type •Silicone Waterproofing •Acrylic Waterproofing By Application •Filming and Photography •Mapping and Surveying •Precision Agriculture •Surveillance and Monitoring Key Companies SwellPro, GPTOYS, PowerVision Robot, DJI, AeroVironment, Parrot, Applied Aeronautics, Tetra Drones, Delta Drone, Autel Robotics, Contixo, AguaDrone, LiDiRC, C-Astral, MikroKopter, Shanghai Huace Navigation View Full Report: https://reports.valuates.com/market-reports/QYRE-Auto-0F13037/global-commercial-waterproof-drone Please reach us at sales@valuates.com Address: Valuates, 4th Floor, Balaraj's Arcade, Whitefield Main road, Bangalore 560066 Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends. This release was published on openPR.Daily news reporting from the field of agriculture, farmers, crime, health, environment, education, politics, and feature articles from Ambala (with coverage of Kurukshetra & Yamunanagar). Read More How to make healthy Oats Palak Chilla for a kid's tiffin 10 best Fried Chicken dishes from around the world 10 ways to use turmeric in winters 10 animals not allowed as pets in India 10 types of Dosa and how they are made Animals and their favourite foods 9 nuts to eat daily for hair growth in winters How to make South Indian Podi Dosa at home From tigers to cheetahs: India’s big cats and where to find them Weekend Special: How to make Multigrain ThaalipeethJim Carrey teases Grinch sequel — but with a twist
Donald Trump has yet to move back into the White House and already fissures are opening in his coalition, amid squabbling between Elon Musk and his Silicon Valley "tech bros" and his hardcore Republican backers. At the heart of the internecine sniping is Trump's central election issue -- immigration -- and the H1-B visas that allow companies to bring foreigners with specific qualifications to the United States. The permits are widely used in Silicon Valley, and Musk -- who himself came to the United States from South Africa on an H1-B -- is a fervent advocate. The world's richest man, who bankrolled Trump's election campaign and has become a close advisor, posted on X Thursday that welcoming elite engineering talent from abroad was "essential for America to keep winning." Vivek Ramaswamy, appointed by Trump as Musk's co-chair on a new advisory board on government efficiency, suggested that companies prefer foreign workers because they lack an "American culture," which he said venerates mediocrity. "A culture that celebrates the prom queen over the math olympiad champ, or the jock over the valedictorian, will not produce the best engineers," he posted, warning that, without a change in attitude, "we'll have our asses handed to us by China." Skepticism over the benefits of immigration is a hallmark of Trump's "Make America Great Again" (MAGA) movement and the billionaires' remarks angered immigration hawks who accused them of ignoring US achievements in technological innovation. Incoming White House deputy chief of staff Stephen Miller posted a 2020 speech in which Trump marveled at the American "culture" that had "harnessed electricity, split the atom, and gave the world the telephone and the Internet." The post appeared calculated to remind critics that Trump won November's election on a platform of getting tough on immigration and boosting American manufacturing. But it was Michael Faraday, an English scientist, who discovered that an electric current could be produced by passing a magnet through a copper wire and Ernest Rutherford, a New Zealander, who first split the atom. And Alexander Graham Bell may have died a US citizen but he was a British subject in Canada when he invented the telephone. Trump voiced opposition to H1-B visas during his successful first run for the White House in 2016, calling them "unfair for our workers" while acknowledging that he used foreign labor in his own businesses. The Republican placed restrictions on the system when he took office, but the curbs were lifted by President Joe Biden. Trump is known for enjoying the gladiatorial spectacle when conflict breaks out in his inner circle. He has been conspicuously silent during the hostilities that Politico characterized as "Musk vs MAGA." Many MAGA figures have been agitating for a complete closure of America's borders while the problem of illegal entries is tackled, and hoping for a steer from Trump that would reassure them that he remains firm in his "America First" stance. For some long-time loyalists, Silicon Valley has already inserted itself too deeply into MAGA politics. "We welcomed the tech bros when they came running our way to avoid the 3rd grade teacher picking their kid's gender -- and the obvious Biden/Harris economic decline," said Matt Gaetz, the scandal-hit congressman forced to withdraw after being nominated by Trump to run the Justice Department. "We did not ask them to engineer an immigration policy." When Musk almost single-handedly blew up a deal painstakingly hammered out between Democrats and Republicans to set the 2025 federal budget, Democrats used "President Musk" to mock Trump, who is famously sensitive about being upstaged. It remains to be seen whether these cracks can be smoothed out or if they are a portent of further strife, but critics point to the chaos in Trump's first term as a potential indicator. "Looking forward to the inevitable divorce between President Trump and Big Tech," said far-right conspiracy theorist Laura Loomer, a MAGA figure with so much influence that she had a seat on Trump's plane during the campaign. "We have to protect President Trump from the technocrats." Loomer has subsequently complained of censorship after she was stripped of her paying subscribers on X, which is owned by Musk. "Full censorship of my account simply because I called out H1B visas," she posted. "This is anti-American behavior by tech oligarchs. What happened to free speech?" rle/ft/sms
Lydia Ko locks in full game in CME Group Tour Championship Round 1Gophers look to duplicate 2019 upset of Penn State on Saturday